search all
browse all
Previous Next

Additional COVID-19 booster vaccination

Object Type: Asset
In Folder: Documents from 2022

Other Documents

sdb:SO|02eaf94c-f3f8-4792-aa7a-516667516bf2
13
Additional COVID-19 booster vaccination

IO_fc3edba0-71e7-45b1-9d19-6382d3c98293

Additional COVID-19 booster vaccination for those aged 18-49 years

IO_74adca50-5d5e-4a54-ae66-d95e52632c23

Letter to Chief Medical Officer. Regarding inclusion of additional cohorts of the population in the booster COVID-19 programme

IO_15f8130e-44e9-48dd-8f72-96695197ae3a

Letter to the Chief Medical Office. Regarding recommendations for Nuvaxovid COVID-19 vaccine (Novavax)

IO_eeee99c1-26d0-47d3-8ceb-adf229fd73e7

Letter to the Chief Medical Office. Regarding recommendations for the use of smallpox (vaccinia) vaccine as pre and post exposure prophylaxis against monkeypox

IO_19aeaa8a-902a-4bc0-b7bf-e2e741cc7f61

Medium term strategy for the COVID-19 vaccination programme: recommendations for second booster dose; future considerations

IO_b889cf70-67aa-48de-a8eb-8b00353fc548

Monkeypox vaccination

IO_710d7d80-7a37-4e20-8f21-2d9eba927c47

Recommendations for COVID-19 booster vaccination of those aged 12-15 years

IO_d07dd225-04e5-42b6-8c19-2b5eac69038a

Recommendations for the use of monkeypox modified vaccinia ankara vaccines, Imvanex or Jynneos, by the intradermal route

IO_4a344d06-3734-4428-b7f8-d740e2107f61

Recommendations regarding HPV vaccine dosage

IO_05f2af2c-4e80-4439-acb7-ab759fb73ca8

Selective strategy for BCG vaccination

IO_8c572e88-025e-4b90-8e87-bc11e40f6f16

Updated recommendations for HPV vaccination

IO_c753db6c-f70f-492c-92d7-50dd758be94e

Updated recommendations regarding bivalent mRNA COVID-19 vaccines

IO_db2ca1bf-9acb-4331-9b2b-2a3a07803ced

Powered by Preservica
© Copyright 2023
©2023 Preservica